DE69430635T2 - Loteprednoletabonat-suspension - Google Patents

Loteprednoletabonat-suspension

Info

Publication number
DE69430635T2
DE69430635T2 DE69430635T DE69430635T DE69430635T2 DE 69430635 T2 DE69430635 T2 DE 69430635T2 DE 69430635 T DE69430635 T DE 69430635T DE 69430635 T DE69430635 T DE 69430635T DE 69430635 T2 DE69430635 T2 DE 69430635T2
Authority
DE
Germany
Prior art keywords
suspension
loteprednol etabonate
etabonate
loteprednol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69430635T
Other languages
English (en)
Other versions
DE69430635D1 (de
Inventor
Yaacov J Guy
Doron Friedman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Inc
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/142,743 priority Critical patent/US5540930A/en
Application filed by Pharmos Corp filed Critical Pharmos Corp
Priority to PCT/US1994/012059 priority patent/WO1995011669A1/en
Publication of DE69430635D1 publication Critical patent/DE69430635D1/de
Application granted granted Critical
Publication of DE69430635T2 publication Critical patent/DE69430635T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • A61K31/787Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79Polymers of vinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/912Ophthalmic
    • Y10S514/914Inflammation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/937Dispersion or emulsion
DE69430635T 1993-10-25 1994-10-21 Loteprednoletabonat-suspension Expired - Lifetime DE69430635T2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US08/142,743 US5540930A (en) 1993-10-25 1993-10-25 Suspension of loteprednol etabonate for ear, eye, or nose treatment
PCT/US1994/012059 WO1995011669A1 (en) 1993-10-25 1994-10-21 Suspension of loteprednol etabonate

Publications (2)

Publication Number Publication Date
DE69430635D1 DE69430635D1 (de) 2002-06-20
DE69430635T2 true DE69430635T2 (de) 2003-01-02

Family

ID=22501105

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430635T Expired - Lifetime DE69430635T2 (de) 1993-10-25 1994-10-21 Loteprednoletabonat-suspension

Country Status (17)

Country Link
US (2) US5540930A (de)
EP (1) EP0730443B1 (de)
JP (1) JP3570720B2 (de)
KR (1) KR100341497B1 (de)
AT (1) AT217523T (de)
AU (1) AU697617B2 (de)
BR (1) BR9407958A (de)
CA (1) CA2174550C (de)
DE (1) DE69430635T2 (de)
DK (1) DK0730443T3 (de)
ES (1) ES2179851T3 (de)
HU (1) HU227316B1 (de)
IL (1) IL111402A (de)
NZ (1) NZ275749A (de)
PT (1) PT730443E (de)
SG (1) SG48768A1 (de)
WO (1) WO1995011669A1 (de)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
US5576311A (en) * 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US5955097A (en) 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
KR100508227B1 (ko) * 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
WO1999037286A1 (fr) * 1998-01-22 1999-07-29 Santen Pharmaceutical Co., Ltd. Collyre a suspension de fluorometholone
US6103266A (en) * 1998-04-22 2000-08-15 Tapolsky; Gilles H. Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
CA2342797A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
TR200103694T2 (tr) * 1999-06-22 2002-04-22 Boehringer Ingelheim International Gmbh Sabit ksilometazolin ve oksimetazolin çözeltisi
FR2796553B1 (fr) * 1999-07-22 2001-09-28 Warner Lambert Co Suspension de tixocortol pivalate, collutoire a base de celle-ci et conditionnement la contenant
DK1214056T3 (da) 1999-09-24 2004-02-09 Alcon Inc Topiske suspensionsformuleringer indeholdende ciprofloxacin og dexamethason
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
EP1142565A4 (de) * 1999-10-20 2004-03-17 Teijin Ltd Wässerige arzneimittel
CN1376066A (zh) * 1999-11-18 2002-10-23 爱尔康公司 H1拮抗剂和安全类固醇的治疗眼病的用途
US20040097486A1 (en) * 1999-11-18 2004-05-20 Yanni John M. Use of an H1 antagonist and a safe steroid to treat eye conditions
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
EP1282401A2 (de) * 2000-05-15 2003-02-12 PHARMACIA & UPJOHN S.p.A. Stabilisierte steroidale suspension
US6462033B2 (en) 2000-07-26 2002-10-08 Alcon Universal Ltd. Process for manufacturing compositions containing ciprofloxacin and hydrocortisone
AT424808T (de) * 2000-11-15 2009-03-15 Chandavarkar Mohan A Pharmazeutische zusammensetzungen mit corticosteroiden und antiinfektiva
WO2002040030A1 (en) * 2000-11-16 2002-05-23 Alcon Manufacturing, Ltd. Combination therapy for lowering and controlling intraocular pressure
DE60208216T2 (de) 2001-09-21 2006-06-29 Alcon Inc. Verfahren zur behandlung von mittelohrinfektionen
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US20090215735A1 (en) * 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
US7727549B2 (en) * 2002-07-15 2010-06-01 Alcon, Inc. Pharmaceutical compositions for otic use
AU2003301263A1 (en) * 2002-10-18 2004-05-04 Joel S. Echols Three layer tear formulation
US20040151754A1 (en) * 2002-12-20 2004-08-05 Control Delivery Systems, Inc. Steroid suspensions for intraocular use
PT1586316E (pt) 2003-01-21 2008-05-28 Senju Pharma Co Preparação líquida aquosa contendo ácido 2-amino-3-(4- bromobenzoil)fenilacético
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050197303A1 (en) * 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
WO2005041980A1 (en) 2003-11-03 2005-05-12 Ivax Corporation Soft steroid compositions for use in dry powder inhalers
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
JP4820648B2 (ja) * 2003-12-02 2011-11-24 千寿製薬株式会社 ロテプレドノールエタボネート水性懸濁液剤
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
EP1713514A2 (de) * 2004-01-28 2006-10-25 The Johns Hopkins University Arzneimittel und genträgerteilchen, die sich schnell durch schleimhautbarrieren bewegen
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
CA2560824A1 (en) * 2004-03-25 2005-10-13 Bausch & Lomb Incorporated Use of loteprednol etabonate for the treatment of dry eye
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
EP1773350B1 (de) * 2004-07-12 2013-05-29 Allergan, Inc. Ophthalmische zusammensetzungen zur behandlung von augenleiden
US8653055B2 (en) * 2004-09-15 2014-02-18 Teva Animal Health, Inc. Corticosteroid having low systemic absorption
DK1906916T3 (da) * 2005-05-10 2009-01-19 Alcon Inc Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser
PT1885336E (pt) * 2005-05-10 2009-05-07 Alcon Inc Formulações de suspensão compreendendo um princípio activo, um tensoactivo poloxâmero ou meroxapol e um glicol, sua utilização no fabrico de um medicamento para tratamento de distúrbios oftálmicos
CA2622001A1 (en) * 2005-09-26 2007-04-05 Piedmont Pharmaceuticals Llc Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear
EP1931388A4 (de) * 2005-09-26 2010-12-15 Piedmont Pharmaceuticals Llc Verfahren zur behandlung und prävention von otitis media mit nichtionischen tensiden zur erleichterung der transmembranösen arzneiabgabe in das mittelohr
AU2006304416B2 (en) 2005-10-18 2013-03-28 Allergan, Inc. Ocular therapy using Glucocorticoid Derivatives selectively penetrating posterior segment tissues
US20070093461A1 (en) * 2005-10-26 2007-04-26 Bausch & Lomb Incorporated Effect of Loteprednol etabonate on vascular dysfunction
WO2013043387A1 (en) 2011-09-22 2013-03-28 Bausch & Lomb Incorporated Ophthalmic gel compositions
WO2007058935A2 (en) * 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20070128251A1 (en) * 2005-12-07 2007-06-07 Piedmont Pharmaceuticals, Inc. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US7955632B2 (en) 2005-12-07 2011-06-07 Bayer B.V. Process for manufacturing chewable dosage forms for drug delivery and products thereof
CA2647348A1 (en) 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
ZA200808114B (en) * 2006-03-28 2009-12-30 Javelin Pharmaceuticals Inc Formulations of low dose non-steroidal anti-inflammatory drugs and betacyclodextrin
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
WO2008002118A1 (es) * 2006-06-27 2008-01-03 Arturo Jimenez Bayardo Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
EP2054031B1 (de) 2006-07-21 2016-04-06 BioDelivery Sciences International, Inc. Transmukosale abgabevorrichtungen mit verbesserter aufnahme
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
WO2008027341A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
DE602007012559D1 (de) * 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
WO2008057360A1 (en) * 2006-11-02 2008-05-15 Riolan Technologies, Inc. Methods of treating an ocular allergy with low dose dexamethasone
US20090023668A1 (en) * 2006-11-02 2009-01-22 Friedlaender Mitchell H Method for treating blepharitis
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
CN101721714B (zh) * 2009-12-18 2011-12-07 重庆莱美药业股份有限公司 实体瘤被动靶向性抗癌前药及其制备方法
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
BR112013026534A2 (pt) * 2011-04-22 2016-12-27 Alcon Res Ltd composição oftálmica com um sistema de realce da viscosidade tendo dois diferentes agentes de realce da viscosidade
MX352959B (es) 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
JP6138904B2 (ja) 2012-03-16 2017-05-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
CA2867381C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Controlled release formulations for the delivery of hif-1 inhibitors
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2013256064B2 (en) 2012-05-03 2018-01-04 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
WO2013166385A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
MX2014013315A (es) * 2012-05-03 2015-09-10 Kala Pharmaceuticals Inc Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa.
JP6392209B2 (ja) 2012-05-04 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
CN103565740A (zh) * 2012-07-25 2014-02-12 天津金耀集团有限公司 依碳氯替泼诺混悬滴眼液
CN103565742A (zh) * 2012-07-25 2014-02-12 天津金耀集团有限公司 氟米龙滴眼液
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN105189462B (zh) 2013-02-20 2017-11-10 卡拉制药公司 治疗性化合物和其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
EP3216451A4 (de) * 2014-11-07 2018-06-13 Santen Pharmaceutical Co., Ltd. Ophthalmische wässrige zusammensetzung
CN106279324A (zh) * 2015-05-27 2017-01-04 天津金耀集团有限公司 依碳氯替泼诺一水合物及其晶型与制备方法
CN106279325A (zh) * 2015-05-27 2017-01-04 天津金耀集团有限公司 一种依碳氯替泼诺新晶型及其制备方法
CN106892952A (zh) * 2015-12-21 2017-06-27 天津金耀集团有限公司 一种依碳氯替泼诺新晶型及其制备方法
CN106892953A (zh) * 2015-12-21 2017-06-27 天津金耀集团有限公司 依碳氯替泼诺一水合物及其晶型与制备方法
EP3509421A4 (de) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Kristalline formen therapeutischer verbindungen und verwendungen davon
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509422A4 (de) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. Kristalline formen von therapeutischen verbindungen und verwendungen davon

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPH0524131B2 (de) * 1983-08-12 1993-04-06 Otsuka Pharma Co Ltd
JPH027574B2 (de) * 1984-08-03 1990-02-19 Takeda Yakuhin Kogyo Kk
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5149693A (en) * 1988-03-09 1992-09-22 Alcon Laboratories, Inc. Combination of tobramycin and fluorometholone for topical ophthalmic use
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5277901A (en) * 1990-01-05 1994-01-11 Allergan, Inc. Ophthalmic compositions and methods for preserving and using same

Also Published As

Publication number Publication date
PT730443E (pt) 2002-11-29
DK0730443T3 (da) 2002-09-09
KR100341497B1 (ko) 2002-12-05
DE69430635D1 (de) 2002-06-20
US5747061A (en) 1998-05-05
AU697617B2 (en) 1998-10-15
US5540930A (en) 1996-07-30
JP3570720B2 (ja) 2004-09-29
AT217523T (de) 2002-06-15
BR9407958A (pt) 1996-11-26
HUT74882A (en) 1997-02-28
JPH09504294A (ja) 1997-04-28
DK730443T3 (de)
EP0730443B1 (de) 2002-05-15
HU9601081D0 (en) 1996-06-28
EP0730443A4 (de) 1997-11-05
IL111402A (en) 2000-12-06
WO1995011669A1 (en) 1995-05-04
AU7983594A (en) 1995-05-22
NZ275749A (en) 1998-02-26
HU227316B1 (en) 2011-03-28
SG48768A1 (en) 1998-05-18
ES2179851T3 (es) 2003-02-01
IL111402D0 (en) 1994-12-29
KR960705541A (ko) 1996-11-08
CA2174550A1 (en) 1995-05-04
CA2174550C (en) 2002-10-01
EP0730443A1 (de) 1996-09-11

Similar Documents

Publication Publication Date Title
DE69430635T2 (de) Loteprednoletabonat-suspension
DE69411848D1 (de) Furanylinsektizide
DE69421035T2 (de) Ringoszillator
DE10299013I1 (de) Aza-Zyklohexapeptide
DE69332805D1 (de) Aspertokinasegenvarianten
AT282366T (de) Wirbeldistraktor
AT164494T (de) Sportschuh
BR9405832A (pt) Imidazoazinas
AT216626T (de) Filterrücksprülsystem
DE69405776T2 (de) Carboxymethylinulin
DE69407270D1 (de) Oxydationsmittel
AT209215T (de) Protegrine
DE69424566D1 (de) Enthaarung
DE69413933D1 (de) Antitussiva
AT296312T (de) Metalkomplexbildner
AT174107T (de) Nutenstein
DE69413019D1 (de) Stickstoff enthaltende kondensierte heterocylen
DE69406531D1 (de) Oxydationsmittel
DE69410500T2 (de) Mehrplattenspieler
DE69421322T2 (de) Cyclopropyl-substituierte Spiro-fotochrome
DE59309062D1 (de) Mischer-Trockner
DE69423900D1 (de) V-jet atomisateur
DE69402867T2 (de) Triglyceridoelfraktionierung
DE69405766T2 (de) Allyl-epoxy-ipn
DE59410180D1 (de) 4-Cyanophenyliminoheterocyclen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BAUSCH & LOMB INC., ROCHESTER, N.Y., US

8364 No opposition during term of opposition